All translational work was carried out by UCL and biotechnology company Personalis.
He received three doses of immunotherapy across nine weeks before undergoing surgery in May 2023.
After nearly three years of follow-up, none of the patients had experienced a cancer recurrence, including those who still had small traces of disease after treatment.